0IFZ Stock Chart & Stats
$65.80
$0.00(0.00%)
At close: 4:00 PM EST
$65.80
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$65.80 - $65.80
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$92.06K
Enterprise Value-$1.18M
Total Cash (Recent Filing)$2.78M
Total Debt (Recent Filing)$762.00K
Price to Earnings (P/E)<0.1
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding41,845,078
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.62
Price to Sales (P/S)0.88
P/FCF Ratio-0.29
Enterprise Value/Market Cap-12.80
Enterprise Value/Revenue-0.02
Enterprise Value/Gross Profit-0.02
Enterprise Value/Ebitda-0.09
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe mesothelin targeted autologous CAR monocyte program is expected to show evidence of clinical responses and clean safety, which should de-risk and validate the monocyte platform.
Strategic PartnershipsCarisma will focus on developing off-the-shelf products using its in vivo macrophage engineering platform, including those under the Moderna partnership.
Bears Say
Program DiscontinuationCarisma Therapeutics announced that it would be discontinuing development of its lead program, CT-0525.
Workforce ReductionAs part of the strategic restructuring, Carisma will reduce its workforce by 34%.
Carisma Therapeutics News
0IFZ FAQ
What was Carisma Therapeutics’s price range in the past 12 months?
Carisma Therapeutics lowest share price was $65.80 and its highest was $65.80 in the past 12 months.
What is Carisma Therapeutics’s market cap?
Carisma Therapeutics’s market cap is $92.06K.
When is Carisma Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Carisma Therapeutics’s earnings last quarter?
Currently, no data Available
Is Carisma Therapeutics overvalued?
According to Wall Street analysts Carisma Therapeutics’s price is currently Overvalued.
Does Carisma Therapeutics pay dividends?
Carisma Therapeutics does not currently pay dividends.
What is Carisma Therapeutics’s EPS estimate?
Carisma Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Carisma Therapeutics have?
Carisma Therapeutics has 41,845,078 shares outstanding.
What happened to Carisma Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Carisma Therapeutics?
Currently, no hedge funds are holding shares in GB:0IFZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Carisma Therapeutics
Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidates include CT-2401, which is in preclinical trial for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others. In addition, it develops in vivo CAR-M cell therapy to treat solid tumors, including hepatocellular carcinoma. Carisma Therapeutics, Inc. has collaboration and license agreement with ModernaTX, Inc. to address oncology gene therapies. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. Carisma Therapeutics, Inc. was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.
Technical Analysis
AIM ImmunoTech
―
GT Biopharma
―
―
Bolt Biotherapeutics
―
CERo Therapeutics Holdings
―